Shield Therapeutics (LON:STX) Shares Down 10% - Here's What Happened

Key Points

• Shield Therapeutics shares fell by 10% during mid-day trading, dropping from a previous close of GBX 9 ($0.12) to GBX 8.10 ($0.11).
• The company has a market capitalization of £83.49 million and a significantly high debt-to-equity ratio of 3,691.50.
• Shield Therapeutics specializes in pharmaceuticals, delivering Accrufer® to address iron deficiency, with its product recently launched in the U.S.

Shield Therapeutics plc (LON:STX - ) traded down 10% during mid-day trading on Monday . The company traded as low as GBX 7.70 ($0.10) and last traded at GBX 8.10 ($0.11). 8,309,130 shares changed hands during trading, an increase of 202% from the average session volume of 2,753,942 shares. The stock had previously closed at GBX 9 ($0.12).

Shield Therapeutics Trading Down 10.9%

The firm has a market capitalization of £83.49 million, a PE ratio of -400.75 and a beta of 1.42. The firm's fifty day moving average is GBX 5.50 and its two-hundred day moving average is GBX 3.67. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.